Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 527 results found. Search for [ covid-19 human trials ]

Results 1 to 21 of 527
PTI
June 12, 2021
Ram Vishwakarma, the advisor to the CSIR Director-General, said Colchicine, in combination with standard care, will be an important therapeutic intervention for COVID-19 patients with cardiac co-morbidities


BusinessToday.In
June 6, 2021
Niclosamide has been extensively used in the past for treatment of tapeworm's infection in adults as well as children and its safety profile has been tested over time.


PB Jayakumar
June 2, 2021
The acquisition of Akorn India helped Biological E create a potential overall manufacturing capacity of over 1 billion doses per annum.


PTI
May 29, 2021
The company has received approval from the US Food and Drug Administration (USFDA) to market in the US its generic version in strengths of 1 mg, 2.5 mg, 5 mg, and 10 mg, Zydus Cadila said in a statement


PTI
May 29, 2021
IIL's Managing Director K Anand Kumar said the firm is expected to produce the drug substance initially for 2-3 million doses per month


PB Jayakumar
May 28, 2021
While official data shows 2.1 crore doses of Covaxin had been administered across the country till Thursday, based on statements from Bharat Biotech and Centre, at least 6 crore doses should have been produced and available for vaccination


Reuters
May 27, 2021
India has been inoculating its people with the AstraZeneca vaccine produced locally at the Serum Institute, Covaxin made by local firm Bharat Biotech, and has begun rolling out Russia's Sputnik V


PB Jayakumar
May 27, 2021
Zydus is the only Indian company which claims to have developed a neutralising monoclonal antibodies (mAbs) based cocktail for the treatment of COVID 19


PTI
May 24, 2021
As announced in April, the Russian Direct Investment Fund (RDIF) - which markets the vaccine internationally, and Panacea Biotec agreed to produce 100 million doses per year of Sputnik V in India


BusinessToday.In
May 24, 2021
First batch produced at Panacea Biotec's facilities at Baddi will be shipped to the Gamaleya Centre for quality control. Full-scale production of the vaccine is due to start soon


BusinessToday.In
May 17, 2021
Dr Reddy's Laboratories CEO - Branded Markets (India & Emerging Markets) MV Ramana said the two entities are working to scale up the pilot and take the vaccine to other cities.


Reuters
May 14, 2021
The Russian Direct Investment Fund (RDIF), which is responsible for marketing the vaccine abroad, said the manufacturing capacity for Sputnik V was increasing globally as new manufacturers come on board.


BusinessToday.In
May 11, 2021
Claims linking 5G technology with COVID-19 pandemic are false and have no scientific basis, says the Centre. Testing of 5G network has not even started anywhere in India


Associated Press
May 9, 2021
The Covid-19 vaccine cannot be inhaled via shedding and can only enter the human body through an administered dose


BusinessToday.In
May 4, 2021
Serum Institute of India (SII), which is known globally for its vaccine production capacity is among 20 Indian companies across sectors (healthcare, biotech and software services) to announce massive investment plans in the UK


BusinessToday.In
April 30, 2021
As per the permit, the Telangana government will be able to deploy drones for the experimental delivery of COVID-19 vaccines within the Visual Line of Sight (VLOS) Range


PB Jayakumar
April 26, 2021
World Health Organisation (WHO)'s data on 'Landscape of candidate vaccines in clinical development' says a total of 91 vaccine candidates have reached the clinical development stage


Rashi Bisaria
New Delhi, April 22, 2021
New COVID-19 mutant in Bengal, escapes antibodies' immunity Scientists have found a new lineage of the SARS-CoV-2 virus named 'B.1.618' in India, which is predominantly circulating in West Bengal. This is the second lineage to be identified from the country. The infection through this variant makes plasma therapy as redundant as an investigational treatment. 600% jump in oxygen demand from hospitals Putting tremendous pressure on the nation's medical infrastructure, the latest surge in ...


Joe C Mathew
April 21, 2021
\"Efficacy against SARS-Cov-2 has been established. COVAXIN has demonstrated an excellent safety record in human clinical trials and in usage under emergency use,\" said Dr Krishna Ella, MD & Chairman, Bharat Biotech


BusinessToday.In
April 19, 2021
The Pune-headquartered company had received approval in December last year to start phase 1 and 2 trials for its COVID-19 vaccine candidate.


PAGES 1 OF 27  12345